Loading...
XJPX
4118
Market cap2.10bUSD
Jul 10, Last price  
5,626.00JPY
1D
-0.57%
1Q
9.31%
Jan 2017
18.19%
Name

Kaneka Corp

Chart & Performance

D1W1MN
XJPX:4118 chart
P/E
10.94
P/S
0.42
EPS
514.37
Div Yield, %
2.65%
Shrs. gr., 5y
-1.04%
Rev. gr., 5y
7.05%
Revenues
811.64b
+0.55%
473,170,000,000502,968,000,000449,585,000,000412,490,000,000453,826,000,000469,289,000,000476,462,000,000524,785,000,000552,189,000,000555,227,000,000548,222,000,000596,142,000,000621,043,000,000601,514,000,000577,426,000,000691,530,000,000755,821,000,000762,302,000,000807,200,000,000811,638,000,000
Net income
30.98b
+22.40%
18,363,000,00018,817,000,000-1,850,000,0008,406,000,00011,625,000,0005,402,000,0009,325,000,00013,650,000,00018,033,000,00020,985,000,00020,484,000,00021,572,000,00022,239,000,00014,004,000,00015,831,000,00026,488,000,00023,008,000,00023,221,000,00025,309,000,00030,978,000,000
CFO
50.12b
+21.49%
32,742,000,00039,418,000,00026,464,000,00057,412,000,00034,932,000,00015,842,000,00032,775,000,00033,924,000,00033,602,000,00059,704,000,00048,119,000,00049,750,000,00041,113,000,00039,983,000,00074,040,000,00034,106,000,00028,710,000,00061,911,000,00041,252,000,00050,118,000,000
Dividend
Sep 29, 2026105 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kaneka Corporation, established in Tokyo, Japan, in 1949, functions as a globally diversified manufacturer. The company's extensive chemical and advanced materials portfolio includes a broad spectrum of polyvinyl chloride (PVC) products, such as crosslinked, paste, and chlorinated PVC, alongside PVC-PVAc polymers and acryl grafted-vinyl chloride copolymers. It also provides various chemical additives like impact modifiers, processing aids, specialty additives, and tougheners for thermosetting resins. Its specialized polymer offerings feature silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, biodegradable polymers, high-performance engineering resins for injection molding, materials with zero birefringence, acrylic films, and isobutylene-based thermoplastic elastomers. Beyond polymers, Kaneka manufactures an array of foams, including polypropylene, Kanelite, and extruded polystyrene insulation. Its advanced film products encompass polyimide film, transparent films for optical applications, highly thermally conductive graphite sheets, multi-layer insulation, and transparent conductive films, in addition to thermo-resistant and light-resistant transparent resin products. In the energy and cutting-edge materials sector, Kaneka develops photovoltaic power generation systems for residential, public, and industrial installations. Its innovative product range extends to eco-friendly fur, flame-retardant substances, hair accessories, other novel materials, organic EL lighting panels, and biosurfactants. The corporation also holds a significant presence in healthcare and life sciences. It delivers medical products for intervention, blood purification, and gastroenterology, alongside diagnostic testing equipment, regenerative medicine and cell therapy solutions, and genetic diagnostic products. Its pharmaceutical contributions include low molecular pharmaceutical materials, affinity chromatography resins for monoclonal antibody purification, biopharmaceuticals, transdermal medicines, and even specialized innerwear with shock-absorbing properties. Lastly, Kaneka offers a comprehensive selection of food and nutritional products. This segment covers dairy items, margarines, fats and oils, whipping creams, fillings, baker's yeast and dough improvers, processed fruits, butter, shortening, cacao butter alternatives, various kneading creams, frozen dough, spices, and antifreeze materials. Furthermore, the company supplies specialized pharma and supplemental nutrition solutions, such as coenzyme, lactic-acid bacteria, and other functional foodstuffs, alongside agricultural fertilizers.
IPO date
Oct 31, 1949
Employees
11,545
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT